International Journal of Hematology and Oncology 2022, Vol 32, Num 4 Page(s): 159-166
The Clinical and Demographic Characteristics of Our Cases with Primary Bone Tumors and Soft Tissue Tumors

Zeynep ORUC1, Muhammet A. KAPLAN1, Halis YERLIKAYA1, M. Ali CELIK2, Idris ORUC3, Zuhat URAKCI1, Mehmet KUCUKONER1, Abdurrahman ISIKDOGAN1

1Dicle University, Faculty of Medicine, Department of Medical Oncology, TURKEY
2Dicle University, Faculty of Medicine, Department of Internal Medicine, TURKEY
3Diyarbakır Training and Research Hospital, Internal Medicine, Diyarbakır, TURKEY

Keywords: Sarcoma, Bone tumor, Soft tissue tumor
The current study aimed to investigate the clinical and demographic characteristics of the patients with sarcoma who were treated and followed-up in Dicle University Medical Oncology Department. We retrospectively investigated the medical records of 547 patients who were diagnosed with sarcoma in the Dicle University School of Medicine, Department of Medical Oncology, between 2007 and 2015. When we considered the total number of patients (total 23,264) admitted to our center between 2007 and 2015, the rate of our patients with sarcoma was found to be 2.3% of this total number. Primary bone tumor and soft tissue sarcoma were determined in 32% (n=172) and 68% (n=375) of the patients, respectively. The most frequent histological type was osteosarcoma. The age, location of the primary tumor, adjuvant chemotherapy, location of relapse (local, metastatic), history of smoking, and comorbid diseases showed statistically significant differences between two groups. The overall survival and progression-free survival also did not differ significantly between the primary bone tumors and soft tissue tumors (p= 0.65). The rate of our patients with sarcoma was 2.3% of the total number of patients (total 23,264) admitted to our center. This rate is higher than that in the literature.It is hard to interpret the results of the study, however it has been confirmed that the soft tissue sarcomas and primary bone tumors differ with regard to the age at diagnosis, location of tumor, location of relapse, prevalence of adjuvant chemotherapy and risk factors.